Pancreatic exocrine insufficiency (PEI) is observed in patients with pancreatic diseases, including chronic pancreatitis, cystic fibrosis, and tumors, or after surgical resection. PEI often results in malnutrition, weight loss and steatorrhea, which together increase the risk of morbidity and mortality. Pancreatic enzyme replacement therapy (PERT) with delayed-release pancrelipase is now becoming a standard therapy for pancreatic exocrine insufficiency because it significantly improves the coefficients of fat and nitrogen absorption as well as clinical symptoms, without serious treatment-emergent adverse events.
The current provides a concise information about this drug. Pancreatic diseases are associated with deterioration of the pancreatic parenchyma and physiological functions of pancreas (exocrine and endocrine functions). This deterioration involves atrophic/fibrotic changes that…
